TAT-RasGAP <sub>317-326</sub> kills cells by targeting inner-leaflet–enriched phospholipids
Marc Serulla, Gabriel Ichim, Filip Stojceski, Gianvito Grasso, Sergii Afonin, Mathieu Heulot, Tim Schober, Robyn Roth, Cédric Godefroy, Pierre‐Emmanuel Milhiet, Kushal Kumar Das, Ana J. García‐Sáez, Andrea Danani, Christian Widmann
Abstract
Significance TAT-RasGAP 317–326 can lyse cancer cells in a manner distinct from known programmed cell death pathways through its ability to target specific plasma membrane lipids. The killing properties of this peptide may therefore be difficult for cancer cells to alleviate through resistance-building alterations within known regulated cell death pathways. TAT-RasGAP 317–326 and compounds with similar anticancer activities can potentially complement existing anticancer therapies based on the use of genotoxins or radiation that induce apoptosis.